Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
CLL treatments are advancing—hear Dr. Wierda discuss resistance, remission, and future therapies on the HemOnc Pulse.
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
AMPLIFY trial shows AVO combo achieves deep remissions in CLL patients with high-risk TP53 aberrations.
10-year RESONATE-2 results show ibrutinib delivers lasting survival benefits for CLL/SLL as first-line therapy.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
AMPLIFY trial shows acalabrutinib with venetoclax and obinutuzumab significantly improves PFS over chemoimmunotherapy in CLL.
Zanubrutinib shows PFS benefit over BR in high-risk CLL/SLL patients, per 5-year SEQUOIA trial data.
Targeted therapies reshape CLL treatment, shifting focus from age to comorbidities, and patient preferences.
Targeted therapies reshape CLL care as experts weigh time-limited vs indefinite frontline treatment strategies.
Dr. Vose outlined the biggest takeaways from the CLL session at the 2025 Pan Pacific Leukemia Conference.
Pirtobrutinib demonstrated a superior PFS of 14 months, compared with 8.7 months with investigator’s choice.
Novel agents are reshaping treatment for double-refractory CLL, offering new hope for this tough-to-treat disease.
Dr. Alexey Danilov discusses new therapies and ongoing challenges in the evolving CLL treatment landscape.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Section Editor
Matthew Davids, MD, MMScPhysician and Director, Clinical Research, Dana-Farber Cancer Institute and Associate Professor Harvard Medical School
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.